Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Jan

Today In Oncology

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

WGS-Based Classifier Better Predicts HRD Across Cancer Types

ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70%

Can DNA Testing of Colorectal Polyps Improve Insight Into Genetic Risks

Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Multiple Myeloma Sex Differences in Etiology and Clinical Presentation